Published in Drug Week, August 13th, 2010
"The outcomes of the Phase III SAR trial validate the potential of BDP HFA as a treatment option for patients trying to manage their nasal allergies," said Mark Salyer, General Manager of Teva's Respiratory Division. "The goal of this development program...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week